

FACT SHEET FOR HEALTHCARE PROVIDERS

Access Bio, Inc. - *CareStart* COVID-19 IgM/IgG

July 24, 2020

Coronavirus
Disease 2019
(COVID-19)

This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the *CareStart* COVID-19 IgM/IgG

The *CareStart* COVID-19 IgM/IgG is authorized for the detection of antibodies to SARS-CoV-2 in human serum, plasma (sodium citrate, sodium heparin, or dipotassium EDTA) and venous whole blood (sodium citrate, sodium heparin, or dipotassium EDTA).

All individuals whose specimens are tested with one of these tests will receive the Fact Sheet for Recipients: Access Bio, Inc. - *CareStart* COVID-19 IgM/IgG.

What are the symptoms of COVID-19?

Many individuals with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, fever, difficulty breathing). The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that symptoms include cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, headache, sore throat or new loss of taste or smell. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 5 days, but may range 2-14 days.

Public health officials have identified cases of COVID-19 infection throughout the world, including the United States, which poses risks to public health. Please check the CDC webpage for the most up-to-date information.

What do I need to know about COVID-19 antibody testing?

Current information on COVID-19 for healthcare providers is available at CDC's webpage, *Information for Healthcare Professionals* (see links provided in "Where can I go for updates and more information" section).

- The *CareStart* COVID-19 IgM/IgG can be ordered by healthcare providers to test human serum, plasma (sodium citrate, sodium heparin, or dipotassium EDTA)

This test detects human SARS-CoV-2 antibodies that are generated as part of the human adaptive immune response to the COVID-19 virus and is to be performed on only human serum, plasma (sodium citrate, sodium heparin, or dipotassium EDTA) and venous whole blood (sodium citrate, sodium heparin, or dipotassium EDTA).

and venous whole blood (sodium citrate, sodium heparin, or dipotassium EDTA) to detect if there has been an adaptive immune response to COVID-19, indicating recent or prior infection.

- The *CareStart* COVID-19 IgM/IgG should not be used to diagnose or exclude acute infection and should not be used as the sole basis for treatment or patient management decisions. Direct testing for SARS-CoV-2 should be performed if acute infection is suspected.
- The *CareStart* COVID-19 IgM/IgG is authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate or high complexity tests.
- Please refer to the test-specific instructions for use for additional information.

Specimens should be collected with appropriate infection control precautions. Current guidance for COVID-19 infection control precautions are available at the CDC's website (see links provided in "Where can I go for updates and more information" section).

Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of having COVID-19 as outlined in the CDC *Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19)*. For additional information, refer to CDC *Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19)* (see links provided in "Where can I go for updates and more information" section).

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**

FACT SHEET FOR HEALTHCARE PROVIDERS

Access Bio, Inc. - CareStart COVID-19 IgM/IgG

July 24, 2020

Coronavirus
Disease 2019
(COVID-19)

There are no approved available alternative tests. FDA has issued EUAs for other antibody tests that can be found at

<https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#2019-ncov>.

What does it mean if the specimen tests positive for antibodies against the virus that causes COVID-19?

A positive test result with the CareStart COVID-19 IgM/IgG indicates that antibodies to SARS-CoV-2 were detected, and the individual has potentially been exposed to COVID-19.

Antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection. Individuals may have detectable virus present for several weeks following seroconversion. If IgG antibodies are present, it often indicates a past infection but does not exclude recently infected patients who are still contagious. ***It is unknown how long antibodies to SARS-CoV-2 will remain present in the body after infection and it is not known if they confer immunity to infection. Incorrect assumptions of immunity may lead to premature discontinuation of physical distancing requirements and increase the risk of infection for individuals, their households and the public.***

False positive results may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

The CareStart COVID-19 IgM/IgG has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to individuals could include the following: risk of infection by exposure to persons with active COVID-19. If a recent infection is suspected a false positive result may lead to a recommendation for isolation of the individual, monitoring of household or other close contacts for symptoms, isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 individuals, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy or other unintended adverse effects. ***Due to the risk of false***

positive results, confirmation of positive results should be considered – using a second, different antibody assay that detects the same type of antibodies.

Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making patient management decisions.

All laboratories using this test must follow standard confirmatory testing and reporting guidelines according to their appropriate public health authorities

What does it mean if the specimen tests negative for antibodies against virus that causes COVID-19?

A negative test result with this test means that SARS-CoV-2 specific antibodies were not present in the specimen above the limit of detection. However, individuals tested early after infection may not have detectable antibodies despite active infection; in addition, it is not certain that all infected patients will develop a detectable antibody response to SARS-CoV-2 infection. A negative result should not be used to rule out infection. Direct testing of SARS-CoV-2 should be performed if acute infection is suspected.

The absolute sensitivity of the CareStart COVID-19 IgM/IgG is unknown.

Risks to an individual resulting from a false negative result include: restriction of activities potentially deemed acceptable for individuals with evidence of an antibody response to SARS-CoV-2, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events

What is an EUA?

The United States (U.S.) FDA has made these tests available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Services' (HHS') declaration that circumstances exist to justify the emergency use of *in vitro* diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19.

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling 1-800-FDA-1088

FACT SHEET FOR HEALTHCARE PROVIDERS

Access Bio, Inc. - CareStart COVID-19 IgM/IgG

July 24, 2020

Coronavirus
Disease 2019
(COVID-19)

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable

to believe that this IVD may be effective.

The EUA for the test you received is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

Where can I go for updates and more information?

CDC webpages:

General: <https://www.cdc.gov/COVID19>

Healthcare Professionals:

<https://www.cdc.gov/coronavirus/2019-nCoV/guidance-hcp.html>

Information for Laboratories: <https://www.cdc.gov/coronavirus/2019-nCoV/guidance-laboratories.html>

Laboratory Biosafety: <https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html>

Isolation Precautions in Healthcare Settings:

<https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html>

Specimen Collection: <https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinical-specimens.html>

Infection Control: <https://www.cdc.gov/coronavirus/2019-ncov/infection-control/index.html>

FDA webpages:

General: www.fda.gov/novelcoronavirus

EUAs: (includes links to recipient fact sheet and manufacturer's instructions) <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations>

Manufacturer Contact Information:

Access Bio, Inc.

65 Clyde Road, Suite A
Somerset, NJ 08873 USA

Telephone: 732-783-4040

Fax: 732-873-4043

Website: www.accessbio.net

Email: info@accessbio.net

Technical Support in U.S.:

+1-888-898-1270 (Toll Free)

Email: TShelp@accessbio.net

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**